Loading patent…
OwnerWalter P. Carney, Peter J. Hamer +2inventors
InventorsWalter P. Carney, Peter J. Hamer, Karen Pierce, Sheryl Brown-Shimer
Estimating the term…
The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.
A method to detect a preneoplastic/neoplastic disease associated with an activated ras pathway in a human subject comprising:
The method of claim wherein the sandwich ELISA or equivalent assay comprises the use of monoclonal antibodies.
A method of therapy selection for a human patient with a preneoplastic/neoplastic disease comprising:
A method of monitoring the status of a preneoplastic/neoplastic disease in a patient, and/or monitoring how a patient with a preneoplastic/neoplastic disease is responding to a therapy, comprising immunologically detecting and quantifying serial changes in total ras p21 protein levels in samples of a body fluid taken from said patient over time;
Dependencies are inferred from the claim text.